PMID- 37589510
OWN - NLM
STAT- MEDLINE
DCOM- 20230914
LR  - 20231111
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 58
IP  - 7
DP  - 2023 Oct
TI  - Proton pump inhibitor use and the risk of metachronous gastric cancer after H. 
      pylori eradication in patients who underwent endoscopic resection for gastric 
      neoplasms: A population-based cohort study.
PG  - 668-677
LID - 10.1111/apt.17676 [doi]
AB  - BACKGROUND: The association between proton pump inhibitors (PPI) use and gastric 
      cancer remains controversial. AIMS: To investigate the impact of long-term PPI 
      use on metachronous gastric cancer after Helicobacter pylori eradication in 
      high-risk patients who underwent endoscopic resection of gastric neoplasms. 
      METHODS: Using the Korean National Health Insurance Services database, we 
      identified 1836 PPI users and 12,218 non-users among patients who received H. 
      pylori eradication therapy after endoscopic resection for gastric neoplasms 
      between 2009 and 2014. We then compared the incidence of metachronous gastric 
      cancer between the PPI user and non-user groups. We conducted sensitivity 
      analysis using various time lags and propensity score-matched analysis to ensure 
      the robustness of the results. RESULTS: After a median follow-up of 7.3 years, 
      the incidence of metachronous gastric cancer was significantly higher in the PPI 
      user group than in the non-user group, with a crude hazard ratio of 6.20 (95% 
      confidence interval, 5.78-6.65). After adjustment, PPI use was associated with 
      the development of metachronous gastric cancer, with an adjusted hazard ratio of 
      5.51 (95% confidence interval, 5.12-5.92). The PPI user group was categorised 
      into three subgroups according to the cumulative PPI dose; the increased risk of 
      metachronous gastric cancer remained significant regardless of the PPI dose. 
      Moreover, these results remained robust after applying various time lags and 
      propensity score-matched analyses. CONCLUSIONS: Long-term PPI use is associated 
      with an increased risk of metachronous gastric cancer in patients who undergo H. 
      pylori eradication therapy after endoscopic resection of gastric neoplasms.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Gong, Eun Jeong
AU  - Gong EJ
AUID- ORCID: 0000-0003-3996-3472
AD  - Department of Internal Medicine, Hallym University College of Medicine, 
      Chuncheon, South Korea.
FAU - Jung, Hye-Kyung
AU  - Jung HK
AUID- ORCID: 0000-0002-6653-5214
AD  - Department of Internal Medicine, College of Medicine, Ewha Womans University, 
      Seoul, South Korea.
FAU - Lee, Bora
AU  - Lee B
AD  - Institute of Health & Environment, Seoul National University, Seoul, South Korea.
FAU - Hong, Jitaek
AU  - Hong J
AD  - Department of Internal Medicine, Digestive Disease Center, Inha University 
      College of Medicine, Incheon, South Korea.
FAU - Kim, Jong Wook
AU  - Kim JW
AD  - Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, 
      South Korea.
FAU - Shin, Cheol Min
AU  - Shin CM
AUID- ORCID: 0000-0003-2265-9845
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Youn, Young Hoon
AU  - Youn YH
AUID- ORCID: 0000-0002-0071-229X
AD  - Department of Internal Medicine, Yonsei University Gangnam Severance Hospital, 
      Seoul, South Korea.
FAU - Lee, Kwang Jae
AU  - Lee KJ
AD  - Department of Gastroenterology, Ajou University School of Medicine, Suwon, South 
      Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230817
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
CIN - Aliment Pharmacol Ther. 2023 Nov;58(10):1101-1102. PMID: 37885162
CIN - Aliment Pharmacol Ther. 2023 Nov;58(10):1099-1100. PMID: 37885170
MH  - Humans
MH  - *Stomach Neoplasms/epidemiology/surgery
MH  - *Helicobacter pylori
MH  - Proton Pump Inhibitors/adverse effects
MH  - Cohort Studies
EDAT- 2023/08/17 12:42
MHDA- 2023/09/14 06:42
CRDT- 2023/08/17 09:43
PHST- 2023/06/16 00:00 [revised]
PHST- 2023/05/30 00:00 [received]
PHST- 2023/08/02 00:00 [accepted]
PHST- 2023/09/14 06:42 [medline]
PHST- 2023/08/17 12:42 [pubmed]
PHST- 2023/08/17 09:43 [entrez]
AID - 10.1111/apt.17676 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2023 Oct;58(7):668-677. doi: 10.1111/apt.17676. Epub 2023 
      Aug 17.